Comparable results for oral semaglutide in obesity

23 May 2023
novo_nordisk_flags_large

Novo Nordisk (NOV: N) has already achieved a major breakthrough with its results with injectable semaglutide 2.4mg in obesity, a drug branded as Wegovy.

But now the Danish drugmaker has repeated the trick with once-daily oral semaglutide 50mg, which has been compared for weight management to placebo in 667 adults with obesity or overweight with one or more comorbidities in OASIS 1, a 68-week Phase IIIa trial.

On Tuesday, Novo Nordisk announced headline results. The trial achieved its primary endpoint by demonstrating a statistically-significant and superior weight loss at week 68 with oral semaglutide 50mg versus placebo.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical